Safety and Efficacy of IDegLira Titrated Once Weekly vs Twice Weekly in Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

Date: 
March, 2017
March 3, 2017. This open-label trial evaluated the impact of IDegLira (combined insulin degludec and the glucagon-like peptide-1 inhibitor liraglutide) once or twice weekly in insulin-naïve adults with type 2 diabetes inadequately controlled on metformin ± pioglitazone. A total of 420 patients were randomized to this 32-week non-inferiority trial. IDegLira was titrated either once or twice weekly based on mean pre-breakfast plasma glucose readings. With once-weekly titration, mean A1C decreased from 8.2% to 6.1%; reductions for twice-weekly titration were from 8.1% to 6.0%. In addition, approximately 90% of patients in each arm achieved A1C levels